Drug Profile
Research programme: monoclonal antibody therapeutics - Clean Cells/Federative Research Structure Francois Bonamy/INSERM/OSE Immunotherapeutics
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Clean Cells; Federative Research Structure Francois Bonamy; INSERM; OSE Immunotherapeutics
- Developer Clean Cells; Federative Research Structure Francois Bonamy; OSE Immunotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer